Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH for the advancement of exclusive novel affinity ligands used in monoclonal antibody and non-mAb downstream purification processes. Under the terms of this agreement, Repligen and Navigo will co-develop a portfolio of next generation ligands, utilizing Navigo’s proprietary Precision Capturing™ technology platform. As part of the collaboration, Repligen receives intellectual property rights and exclusivity on all affinity ligands developed with Navigo, and Navigo receives a series of milestone and royalty payments.
This formal agreement expands on a two-year relationship between Repligen and Navigo that has produced a best-in-class Protein A ligand with strong caustic stability and ultra-high binding capacity. Scale-up and validation for manufacturing of this novel ligand is underway at Repligen for near-term commercial production.
Tony J. Hunt, Repligen CEO said, “We are very pleased to solidify our partnership with Navigo on a product portfolio that reinforces Repligen’s market leadership position in bioprocessing and as a market and technology leader in affinity ligands. Navigo’s powerful Precision Capturing™ platform enables Repligen to home in on specific attributes that are most important to product performance. This agreement extends our initial collaboration with Navigo that has delivered a next-generation Protein A affinity ligand with outstanding performance attributes. We look forward to making this ligand available to the marketplace, and to further employing Navigo’s state-of-the-art protein engineering technology to introduce additional high-performance ligands to our bioprocessing customers over the coming years.”
Dr. Henning Afflerbach, Navigo CEO added, “We are delighted to enter into this agreement and expand our relationship with Repligen, a global leader in bioprocessing and affinity ligands. Our work to date demonstrates the strength of our proprietary Precision Capturing™ platform to create extremely stable and high-capacity ligands, compatible with state-of-the-art industrial downstream processing. Our large and versatile ligand libraries are based on concepts from broadly applied Protein A biology, and as such are applicable not only to antibody purification, but also to a broader range of biopharmaceuticals including recombinant proteins, vaccines, viral vectors and others. We are convinced that our Precision Capturing™ platform is remarkably well-paired with Repligen’s overall bioprocessing business and their understanding of market needs.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: July 2, 2018
Source: Nasdaq